Serious, sometimes life-threatening and fatal cases of diabetic ketoacidosis (DKA) have been reported in patients on sodium glucose co-transporter 2 (SGLT2) inhibitors for type 1 and type 2 diabetes, warns medicines regulator Health Canada.
In a number of these cases, the presentation of the condition was atypical with only moderately increased blood glucose levels observed. SGLT2 inhibitors are not indicated for treatment of type 1 diabetes mellitus and should not be used in type 1 diabetes.
These drugs include AstraZeneca's (LSE: AZN) Farxiga (dapagliflozin) and Xigduo (dapagliflozin and metformin), Johnson & Johnson’s (NYSE: JNJ) Invokana (canagliflozin) and Jardiance (empagliflozin) from Boehringer Ingelheim.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze